Despite their favourable survival outcomes, the median progression‐free survival (PFS) of patients with advanced NSCLC treated with PD‐1/PD‐L1 inhibitors plus chemotherapy is only 5–8 months.5, 6, 7. Here, CD274 is linked to non-small cell lung carcinoma.